Publications by authors named "O Spinelli"
The GIMEMA LAL2317 protocol investigated the frontline chemotherapy-blinatumomab combination in adult Philadelphia- CD19+ B-lineage acute lymphoblastic leukemia (Ph- B-ALL) to improve minimal residual disease (MRD) response and clinical outcome. Two cycles of intravenous blinatumomab were administered after chemotherapy cycles 3 and 6. The primary endpoint was the rate of molecular MRD negativity following blinatumomab 1.
View Article and Find Full Text PDFVacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) is a haemato-inflammatory syndrome genetically defined by somatic mutations in the X-linked UBA1 gene, typically Val/Thr/Leu substitutions at the Met41 hotspot. Clinical manifestations are heterogeneous and refractory to most haemato-rheumatological treatments. To date, no guidelines exist for the management of VEXAS, and scarce is the evidence on methodology and clinical significance of longitudinal UBA1 clonal burden evaluation upon therapy.
View Article and Find Full Text PDFArticle Synopsis
- Acute lymphoblastic leukemia (γδ T-ALL) is a rare and complex condition in children, prompting a study of 200 pediatric cases to identify its clinical and genetic characteristics.
- The research revealed that very young children (under 3 years) with γδ T-ALL face a significantly high risk and display specific genetic changes, particularly involving STAG2 inactivation and LMO2 activation.
- Importantly, their findings suggest that targeting DNA repair pathways linked to STAG2 inactivation with specific drugs could offer new treatment options and help classify patients based on their risk levels.
Article Synopsis
- - Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the only curative treatment for patients with Myelodysplastic syndromes (MDS), traditionally evaluated using the International Prognostic Scoring System-Revised (IPSS-R).
- - Recent advancements in next generation sequencing have led to the development of molecular prognostic scores like IPSS-M, which provide more detailed risk assessment for MDS patients.
- - A study analyzing 57 MDS patients showed that nearly half were re-stratified from IPSS-R to IPSS-M, indicating better prognostic value with IPSS-M, particularly highlighting that very high-risk patients had worse post-transplant outcomes, underscoring the importance of molecular data